<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 28, 2019 (HealthDay News) — Individuals with chronic kidney disease (CKD) have elevated cardiac biomarkers and are at increased risk for adverse cardiovascular events, according to research published online Oct. 23 in Mayo Clinic Proceedings<\/i>.<\/p>\n
Shravya Vinnakota, M.B.B.S., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective review of 1,981 individuals aged \u226545 years from a population-based sample classified based on estimated glomerular filtration rate (eGFR): group I (>90 mL\/min\/1.73 m\u00b2), group II (60 to 89 mL\/min\/1.73 m\u00b2), and group III (<60 mL\/min\/1.73 m\u00b2; CKD). Age- and sex-adjusted baseline characteristics, tertiles of N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT), and their interactions with eGFR were examined.<\/p>\n
Overall, 819, 1,036, and 126 (6.4 percent) participants were classified as groups I, II, and III\/CKD, respectively. The researchers found that CKD correlated with an increased risk for myocardial infarction (hazard ratio, 1.95) and composite cardiovascular outcomes, including MI, congestive heart failure, stroke, and all-cause mortality (hazard ratio, 1.38) during a 10.2-year follow-up period. The risk for cardiovascular events was increased for individuals with NT-proBNP or hs-TnT in the third tertile, although there were no significant correlations between eGFR and levels of NT-proBNP and hs-TnT.<\/p>\n
“As we better define the cardiovascular burden in this population, there is an emphasis on identifying such factors that may predict cardiovascular outcomes and identify targets for aggressive preventive therapies,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n